PRCT250516P52500
- 0.95
- 0.000.00%
PROCEPT BioRobotics Newsroom
Jefferies Maintains PROCEPT BioRobotics(PRCT.US) With Hold Rating
Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT), Intuitive Surgical (ISRG) and Bio-Rad Laboratories (BIO)
Buy Rating for PROCEPT BioRobotics: Promising Growth in Cancer Treatment Market and BPH Advancements
TD Cowen Maintains PROCEPT BioRobotics(PRCT.US) With Buy Rating, Maintains Target Price $85
B of A Securities Maintains Buy on PROCEPT BioRobotics, Lowers Price Target to $84
PROCEPT BioRobotics Analyst Ratings
PROCEPT BioRobotics (PRCT) Gets a Hold From BTIG
Morgan Stanley Maintains PROCEPT BioRobotics(PRCT.US) With Buy Rating, Maintains Target Price $95
William Blair Maintains PROCEPT BioRobotics(PRCT.US) With Buy Rating
Positive Outlook for PROCEPT BioRobotics: Strong Sales and Growth Justify Buy Rating
Piper Sandler Maintains PROCEPT BioRobotics(PRCT.US) With Buy Rating, Maintains Target Price $100
Truist Financial Maintains PROCEPT BioRobotics(PRCT.US) With Buy Rating, Cuts Target Price to $70
PROCEPT BioRobotics Analyst Ratings
Truist Cuts Price Target on PROCEPT BioRobotics to $70 From $90, Keeps Buy Rating
BTIG Maintains PROCEPT BioRobotics(PRCT.US) With Hold Rating
Analysts Offer Insights on Healthcare Companies: KalVista Pharmaceuticals (KALV), Humana (HUM) and PROCEPT BioRobotics (PRCT)
William Blair Maintains PROCEPT BioRobotics(PRCT.US) With Buy Rating
William Blair Maintains PROCEPT BioRobotics(PRCT.US) With Buy Rating
Buy Rating on PROCEPT BioRobotics: Attractive Entry Point Amidst Growth Potential and Upcoming Clinical Catalysts
Jefferies Maintains PROCEPT BioRobotics(PRCT.US) With Hold Rating, Maintains Target Price $77